A Phase II, Open-label, Single-center Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
Latest Information Update: 24 Jul 2020
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Phytotech
- 05 Sep 2018 Status changed from recruiting to completed.
- 24 Jul 2018 Results presented in a Harvest One Cannabis Media Release.
- 01 Feb 2018 According to a Harvest one media release, the completion of this Phase 2 clinical trial has been earmarked for the middle of 2018.